

# Benign Breast Disease *and* Breast Cancer Risk

Jean F. Simpson, M.D.  
Vanderbilt University  
Nashville, Tennessee  
December 1, 2011

---

---

---

---

---

---

---

Nashville



---

---

---

---

---

---

---

Nashville



Lebanon

---

---

---

---

---

---

---



Cedars of Lebanon State Park

---

---

---

---

---

---

---

---

The American University of Beirut



Dr. Fouad Boulos



Dr. Doha Itani



Dr. Sharazad Saab

Vanderbilt University

---

---

---

---

---

---

---

---

## Pre-malignant Breast Disease

- **1950-1980**-confusing
  - “ The female breast is a precancerous organ”
  - .....Fred Steward, AFIP fascicle
- **1980-1990** – risk defining
- **2000's** –refining
  - Impact of breast imaging
  - Mimics
  - Molecular aspects

---

---

---

---

---

---

---

---

## Risk Factors for Breast Cancer in Women with Proliferative Breast Disease

Dupont and Page, *NEJM* 1985

10,542 benign breast biopsies

1950-1968

85% follow up at 20 years

---

---

---

---

---

---

---

---

## Nashville Breast Cohort Studies

- Specific histologically-defined terms linked to levels of later malignancy risk
- Regionality of risk, i.e. local vs. diffuse

---

---

---

---

---

---

---

---

## Stratification of Breast Cancer Risk

- No proliferative disease = NO ↑ RISK
- Proliferative disease, no atypia = SLIGHT RISK
- Atypical hyperplasia = MODERATE RISK

---

---

---

---


---

---

---

---

## Distribution of Breast Lesions Nashville series (1950-1968)




---

---

---

---


---

---

---

---

## Distribution of Mammographically Detected Lesions



Rubin et al, Cancer 1988

---

---

---

---

---

---

---

---

## Stratification of Breast Cancer Risk

- No proliferative disease = NO ↑ RISK
- Proliferative disease, no atypia = SLIGHT RISK
- Atypical hyperplasia = MODERATE RISK

---

---

---

---

---

---

---

---

## Relative Risk

- Used to compare groups (not individuals), one group has characteristic, control group does not
- Slight increase risk = amount detectable in population
- Statistically significant, but not significant for patients

---

---

---

---

---

---

---

---

## Moderate Alcohol Consumption During Adult Life, Drinking Patterns, and Breast Cancer Risk

- Nurse's Health Study
- Prospective observational study
- 105,986 women, entered 1980-2008

Chen et al, JAMA Nov 2, 2011

---

---

---

---

---

---

---

---

## Nurse's Health Study: risk of alcohol consumption

alcohol per week	relative risk	CI
3-6 drinks	1.15	(1.06-1.26)
6-10 drinks	1.15	(1.06-1.24)
13-19 drinks	1.28	(1.12-1.47)
>19 drinks	1.50	(1.34-1.67)

Chen et al, JAMA Nov 2, 2011

---

---

---

---

---

---

---

---

## Nurse's Health Study: risk of alcohol consumption

alcohol per week	relative risk	CI
3-6 drinks	1.15	(1.06-1.26)
6-10 drinks	1.15	(1.06-1.24)
13-19 drinks	1.28	(1.12-1.47)
>19 drinks	1.50	(1.34-1.67)

Chen et al, JAMA Nov 2, 2011

**Slight increase in risk**

---

---

---

---

---

---

---

---

## Relative Risk for Developing Cancer After Benign Biopsy

- No increased risk
  - cysts
  - duct ectasia
  - adenosis
  - hyperplasia, mild
- Slightly increased risk
  - Early menarche
  - Late menopause
  - Nulliparity
- Moderately increased risk
  - Atypical ductal hyperplasia
  - Atypical lobular hyperplasia

---

---

---

---

---

---

---

---

## Relative Risk

Women with PD who develop breast cancer

Women with PD, no cancer development

RR =

Women in the general public who develop breast cancer

Women in the general public, no cancer development

---

---

---

---

---

---

---

---

## Relative Risk

**Women with PD who develop breast cancer**

Women with PD, no cancer development

RR =  $\frac{\text{Women with PD who develop breast cancer}}{\text{Women with PD, no cancer development}}$

**Women in the general public who develop breast cancer**

Women in the general public, no cancer development

---

---

---

---

---

---

---

---

## Relative Risk

**Women with PD who develop breast cancer**

Women with PD, no cancer development

RR =  $\frac{\text{Women with PD who develop breast cancer}}{\text{Women with PD, no cancer development}}$

**Women in the general public who develop breast cancer**

Women in the general public, no cancer development

---

---

---

---

---

---

---

---

## Relative Risk

**Women with PD who develop breast cancer**

Women with PD, no cancer development

RR =  $\frac{\text{Women with PD who develop breast cancer}}{\text{Women with PD, no cancer development}}$

**Women in the general public who develop breast cancer**

Women in the general public, no cancer development

---

---

---

---


---

---

---

---

## Relative Risk Varies with Time Since Diagnosis




---

---

---

---

---

---

---

---

---

---

## Relative Risk for Developing Cancer After Benign Biopsy

- No increased risk
  - cysts
  - duct ectasia
  - adenosis
  - hyperplasia, mild
- Slightly increased risk
  - hyperplasia, moderate or florid, no atypia
  - sclerosing adenosis
  - solitary papilloma
- Moderately increased risk
  - Atypical ductal hyperplasia
  - Atypical lobular hyperplasia

---

---

---

---

---

---


---

---

---

---

### DCIS vs ADH vs FHWA: cytology and histology




---

---

---

---

---

---

---

---

---

---





---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### Relative Risk for Developing Cancer After Benign Biopsy

- No increased risk
  - cysts
  - duct ectasia
  - adenosis
  - hyperplasia, mild
- Slightly increased risk
  - hyperplasia, moderate or florid, no atypia
  - sclerosing adenosis
  - solitary papilloma
- Moderately increased risk
  - Atypical ductal hyperplasia
  - Atypical lobular hyperplasia

---

---

---

---


---

---

---

---

DCIS vs ADH vs FHWA: cytology and histology




---

---

---

---

---

---

---

---

## Minimum Criteria for DCIS

- Uniform population of cells, maintaining rounded, geometric configurations
- Even cell placement, without swirling or streaming
- **Fully** populating two adjacent spaces (3 mm)

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### Atypical Ductal Hyperplasia

- Uniform cytology
- Architecture
  - cribriform, micropapillary, solid
- Extent

---

---

---

---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### Nashville Breast Cohort Study Design

- Define histologic categories that could be reproducibly recognized
- Perform patient follow up
- Assign risk based on cancer development

---

---

---

---

---

---

---

---

### Relative Risk for Developing Cancer After Benign Biopsy

- |  |  |
|--|--|
| <ul style="list-style-type: none"><li>• No increased risk<ul style="list-style-type: none"><li>– cysts</li><li>– duct ectasia</li><li>– adenosis</li><li>– hyperplasia, mild</li></ul></li></ul> | <ul style="list-style-type: none"><li>• Slightly increased risk<ul style="list-style-type: none"><li>– hyperplasia, moderate or florid, no atypia</li><li>– sclerosing adenosis</li><li>– solitary papilloma</li></ul></li></ul> |
|--|--|
- 
- Moderately increased risk
    - Atypical ductal hyperplasia
    - Atypical lobular hyperplasia

---

---

---

---

---

---

---

---

## Confirmatory Studies

Pathologic finding	Nashville Cohort (1985)	Nurse's Health Study (1992)	Breast Cancer Detection Project (1993)	Mayo Clinic (2005)
Proliferative disease without atypia	1.5-2X	1.6X	1.3X	1.9X
Atypical hyperplasia	4-5X	3.7X	4.3X	4.24X

---

---

---

---

---

---

---

---

## Proliferative Mimics

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---


---

---

---

---





---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### Confounders

- Mammography
- Minimally invasive biopsy procedures
- Hyperplasia in unusual settings

---

---

---

---

---

---

---

---

## Underdiagnosis of ADH

- Core needle biopsy 41%
- Mammotome 15%
  
- Core needle biopsy (14 g) 44%
- Mammotome (14 g) 39%
- Mammotome (11g) 19%

Jacobs et al, Am J Surg Pathol, 2002

---

---

---

---

---

---

---

---

## Factors Influencing Underdiagnosis of ADH

- Device used
- Extent of removal of mammographic lesion
- Microcalcifications vs mass

Jacobs et al, AM J Surg Pathol, 2002

---

---

---

---

---

---

---

---

## When to excise after core biopsy?

- Diagnostic difficulty
  
- Sampling issues

---

---

---

---

---

---

---

---

## Atypical Ductal Hyperplasia

- Uniform cytology
- Architecture
- Extent

---

---

---

---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### Extent of ADH on Core Biopsy (n=47)

	Findings in Excised Specimen		
	benign	ADH	DCIS
# ADH foci			
≤2	14	7	0
3	0	4	3
≥4	0	2	12

Ely et al, Am J Surg Pathol, 2001

---

---

---

---

---

---

---

---

### Extent of ADH on Core Biopsy (n=42)

	Findings in Excised Specimen		
	benign	ADH	DCIS
# ADH foci			
1	14	7	0
2	2	5	0
3	3	1	1
≥4	5	2	2

Sneige et al, Am J Clin Pathol, 2003

---

---

---

---

---

---

---

---

### ADH vs low grade DCIS

“At least atypical ductal hyperplasia,  
excision necessary to evaluate extent  
of the lesion”

---

---

---

---

---

---

---

---

## ADH vs DCIS

- Differential diagnosis is LOW GRADE DCIS
- Extent of involvement is key
- Be conservative on core biopsy

---

---

---

---

---

---

---

---

## Biomarkers of ADH?

- ADH is typically negative for HMW keratins (CK 5/6) and diffusely positive for ER
- Usual hyperplasia shows variable expression of HMW keratins and ER
- Expression of these markers is similar in ADH and low-grade DCIS
- None is sufficiently validated for routine clinical use

---

---

---

---

---

---

---

---

## Molecular analysis of ADH

- LOH & CGH show common patterns of genetic alteration in ADH, low grade DCIS, and invasive carcinoma
- Frequent sites of LOH in ADH and invasive carcinoma: chromosomes 16q, 17p, and 11q13
- studies of ADH are from cases of established cancer, both invasive and in situ
- Few studies of ADH as the most advanced lesion
- No studies have established significance of these changes through large, clinically validated patient cohorts.

---

---

---

---

---

---

---

---





---

---

---

---

---

---

---

---